ATE109004T1 - Toleranzinduktion gegenüber einem fremdantigen. - Google Patents

Toleranzinduktion gegenüber einem fremdantigen.

Info

Publication number
ATE109004T1
ATE109004T1 AT89907436T AT89907436T ATE109004T1 AT E109004 T1 ATE109004 T1 AT E109004T1 AT 89907436 T AT89907436 T AT 89907436T AT 89907436 T AT89907436 T AT 89907436T AT E109004 T1 ATE109004 T1 AT E109004T1
Authority
AT
Austria
Prior art keywords
antigen
foreign antigen
tolerance induction
mammal
receptor
Prior art date
Application number
AT89907436T
Other languages
English (en)
Inventor
Terry B Strom
Vicki E Kelley
Original Assignee
Beth Israel Hospital
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Hospital, Brigham & Womens Hospital filed Critical Beth Israel Hospital
Application granted granted Critical
Publication of ATE109004T1 publication Critical patent/ATE109004T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
  • Peptides Or Proteins (AREA)
  • Manufacturing Of Steel Electrode Plates (AREA)
AT89907436T 1988-05-19 1989-05-18 Toleranzinduktion gegenüber einem fremdantigen. ATE109004T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19603688A 1988-05-19 1988-05-19

Publications (1)

Publication Number Publication Date
ATE109004T1 true ATE109004T1 (de) 1994-08-15

Family

ID=22723875

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89907436T ATE109004T1 (de) 1988-05-19 1989-05-18 Toleranzinduktion gegenüber einem fremdantigen.

Country Status (6)

Country Link
EP (1) EP0414816B1 (de)
JP (1) JPH03504248A (de)
AT (1) ATE109004T1 (de)
CA (1) CA1340494C (de)
DE (1) DE68917138T2 (de)
WO (1) WO1989011287A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5152980A (en) * 1988-05-19 1992-10-06 The Beth Israel Hospital Association Induction of tolerance to a foreign antigen IL-2 receptor-binding substances
JPH05508634A (ja) * 1990-07-05 1993-12-02 アクゾ・エヌ・ヴエー レセプター特異的トキシン結合体
EP0721340A1 (de) * 1991-03-07 1996-07-17 Seragen, Inc. Verwendung von auf den zelloberflächenrezeptor gerichtete moleküle zur behandlung von viralen erkrankungen
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
US11203626B2 (en) 2016-03-10 2021-12-21 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
BR112018068055A2 (pt) * 2016-03-10 2019-01-08 Univ Johns Hopkins métodos para produção de proteínas de fusão de toxina da difteria monoméricas livre de agregados e usos terapêuticas
US11965009B2 (en) 2016-03-10 2024-04-23 The Johns Hopkins University Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1203672B (it) * 1982-05-12 1989-02-15 Harvard College Proteina ibrida comprendente frammenti proteici collegati da legami peptidici e relativo gene di fusione composizione contenente tale proteina
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
GB8608068D0 (en) * 1986-04-02 1986-05-08 Cobbold S P Monoclonal antibodies

Also Published As

Publication number Publication date
EP0414816A1 (de) 1991-03-06
EP0414816B1 (de) 1994-07-27
DE68917138D1 (de) 1994-09-01
DE68917138T2 (de) 1995-02-23
CA1340494C (en) 1999-04-13
JPH03504248A (ja) 1991-09-19
WO1989011287A1 (en) 1989-11-30
EP0414816A4 (en) 1991-11-13

Similar Documents

Publication Publication Date Title
ZA91559B (en) Vaccines against cancer and infectious diseases
ZA837603B (en) Immunogenic protein or peptide complex,method of producing said complex and the use thereof as an immune stimulant and as a vaccine
DE3679708D1 (de) Verfahren zur verleihung von immuntoleranz gegen ein spezifisches antigen.
DK190387D0 (da) Vaccine
FI873141A0 (fi) Daeggdjurs interleukin-4.
DK0466037T3 (da) Fremgangsmåde til fremstilling af et gærglucan
DE3850033D1 (de) Teilchenbeschleuniger.
DK543488A (da) Midler til stimulering af et pattedyrs immunreaktion over for gnrh samt et modificeret gnrh og en vaccine til inhibering af et pattedyrs reproduktionsevne
CA2078235A1 (en) Idiotypic vaccination against b cell lymphoma
FI854257A0 (fi) Orala vacciner.
FR2522967B1 (fr) Conjugues d'haptenes et de muramyl-peptides, doues d'activite immunogene et compositions les contenant
NZ189756A (en) Muramyl peptides antigens covalently bonded to muramyl-peptides medicaments and vaccines
RU93004915A (ru) Липосомы, осуществляющие тимус-зависимую помощь "слабым" антигенам, используемым для приготовления вакцины
DE68917138D1 (de) Toleranzinduktion gegenüber einem fremdantigen.
SE8902148L (sv) Syntetiska peptid antigen foer detektion av htlv-1 infektion
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
AU1308288A (en) Method to stimulate the immune response to specific antigens
GB2020665A (en) Acyl-N-acetylmuramylpeptide- antigen conjugate
FI885868A7 (fi) Menetelmä immuunikatoviruksen vasta-aineiden havaitsemiseksi
EP0254845A3 (de) Immun-Stimulation mit Chondroitin-sulfat
KR890701743A (ko) B형 간염 표면 항원 백신
PT636030E (pt) Vacina de bacterina-toxoide de pasteurella haemolytica tipo a-1
SE8803062D0 (sv) Sequential polypeptides endowed with immunological activity
ATE162724T1 (de) Impfstoff gegen schweinedysenterie mit vermindertem gehalt an proteinuntereinheit
DE68926294D1 (de) Antigen gegen diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee